Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00389987
Status:
COMPLETED
Last Update Posted:
2017-02-17
First Post:
2006-10-18
Brief Title:
Ertapenem Sodium vs PiperacillinTazobactam in the Treatment of Complicated Intra-Abdominal Infections 0826-037
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Prospective Multicenter Double-Blind With In-House Blinding Randomized Comparative Study to Evaluate the Efficacy Safety and Tolerability of Ertapenem Sodium Versus PiperacillinTazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to compare the efficacy of ertapenem and piperacillintazobactam with respect to the clinical response in baseline microbiologically evaluable patients and to evaluate the tolerability and safety of ertapenem compared to piperacillintazobactam
Detailed Description:
Original label approved November 2001
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006_538 | None | None | None |